Music exposure is a potential therapy in neuropsychiatric diseases including epilepsy. The ‘Mozart effect’ in epilepsy has been the subject of numerous previous studies. It refers to the observation that listening to Mozart lowers the number of epileptic seizures and the frequency of abnormal brain activity in patients with epilepsy. Prof. Ivan Rektor (Masaryk University, Czech Republic) presented a study comparing the effects of listening to Mozart with listening to Haydn [1].
A total of 18 candidates for epilepsy surgery had intracerebral electrodes implanted in the temporal cortex. They listened to Mozart’s piano sonata and to Haydn’s ‘Surprise’ symphony. Musical features with respect to rhythm, melody, and harmony were analysed. “To our surprise, the effects of listening to Mozart and Haydn were significantly different,” Prof. Rektor said. “Listening to Mozart’s K448 led to a 32% decrease in EDs, but listening to Haydn’s No. 94 caused a 45% increase.” The acoustic features of music composition appear to have a different effect on men compared with women. Listening to Haydn’s music was associated with a suppression of EDs in women, but with an increase in men. The reduction in EDs was larger in the lateral temporal lobe, which participates in translating acoustic signals, rather than in the mesiotemporal limbic region, which plays an important role in the emotional response to music.
“The effects of listening to music on epilepsy cannot be explained by the effect of dopamine released by the reward system,” according to Prof. Rektor. “Our patients were not music connoisseurs and said they were emotionally indifferent to both pieces of music.” Since the acoustic characteristics of music seem to be responsible for suppressing brain epileptic activity, Prof. Rektor suggested the use of musical pieces with well-defined acoustic properties to reduce epileptic activity in epilepsy patients.
- Rektor I, et al. The Mozart effect. Why is Mozart better than Haydn? EPR-145, EAN 2021 Virtual Congress, 19–22 June.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Dexamethasone not indicated for chronic subdural haematoma Next Article
Hypersensitivity to uncertainty in subjective cognitive decline »
« Dexamethasone not indicated for chronic subdural haematoma Next Article
Hypersensitivity to uncertainty in subjective cognitive decline »
Table of Contents: EAN 2021
Featured articles
Letter from the Editor
COVID-19
First evidence of brainstem involvement in COVID-19
Cognitive/behavioural alterations persistent after COVID-19
Neural base of persistent hyposmia after COVID-19
Neurological symptoms and complications of COVID-19 affect outcomes
Cerebrovascular Disease
Intracerebral haemorrhage only slightly increases mortality in COVID-19 patients
Stroke with covert brain infarction indicates high vascular risk
Expanding precision medicine to stroke care
Dexamethasone not indicated for chronic subdural haematoma
Cognitive Impairment and Dementia
Severe outcomes of COVID-19 in patients with dementia
Promising diagnostic accuracy of plasma GFAP
Sex modulates effect of cognitive reserve on subjective cognitive decline
Hypersensitivity to uncertainty in subjective cognitive decline
Epilepsy
Minimally invasive device to detect focal seizure activity
‘Mozart effect’ in epilepsy: why Mozart tops Haydn
Migraine and Headache
Factors associated with decreased migraine attack risk
Pregnant migraine patients at higher risk of complications
Occipital nerve stimulation in drug-resistant cluster headache
Rhythmicity in primary headache disorders
Multiple Sclerosis and NMOSD
Typing behaviour to remotely monitor clinical MS status
Alemtuzumab in treatment-naïve patients with aggressive MS
No higher early MS relapse frequency after stopping ponesimod
Good long-term safety and efficacy of inebilizumab in NMOSD
Neuromuscular Disorders
Inability to recognise disgust as first cognitive symptom of ALS
Pathogenic T-cell signature identified in myasthenia gravis
Parkinson’s Disease
Levodopa-carbidopa intestinal gel in patients with advanced PD
New Frontier – Navigated Transcranial Ultrasound
Exploring the possibilities
Related Articles
August 18, 2021
First evidence of brainstem involvement in COVID-19
August 18, 2021
Pregnant migraine patients at higher risk of complications
August 18, 2021
Alemtuzumab in treatment-naïve patients with aggressive MS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com